Medullary Thyroid Carcinoma

• EMA approval · 2026-02-27
  EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

  The European Medicines Agency authorised Cometriq (cabozantinib) for thyroid neoplasms, with Ipsen Pharma as the marketing authorisation hol…

• FDA approval · 2026-01-27
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• EMA approval · 2025-12-08
  EMA Authorised: Caprelsa (vandetanib) — Sanofi B.V.

  The European Medicines Agency authorised Caprelsa (vandetanib) for thyroid neoplasms, including medullary thyroid carcinoma, with Sanofi B.V…

• FDA approval · 2025-10-09
  FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)

  FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc.

• FDA approval · 2025-09-23
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA notes a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation, related to an update to its approved la…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2025-06-26
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2025-05-14
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation. This action updates the existing NDA…

• CLINICAL_TRIALS approval · 2025-01-17
  Clinical Trial Update: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

  Eli Lilly's RET inhibitor selpercatinib (Retevmo) has been approved for marketing to treat cancers driven by RET activation, including non-s…

• FDA approval · 2024-06-12
  FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

  FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly and Company.

• FDA approval · 2024-04-10
  FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

  FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, expanding its labeled indications for RET fusion–positiv…

• FDA approval · 2023-04-13
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation. The supplemental submission has been app…

• FDA approval · 2022-03-28
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2020-10-22
  FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)

  FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc. The action updates the labeling for the prod…

• FDA approval · 2020-06-15
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2018-10-12
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2017-05-16
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2016-07-28
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  The FDA approved a supplemental application for Caprelsa (vandetanib) from Genzyme Corporation.

• FDA approval · 2014-03-31
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2014-02-28
  FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)

  The FDA approved a supplemental application for COMETRIQ (cabozantinib) from Exelixis, Inc. This approval updates the drug's labeling.

• FDA approval · 2013-07-03
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2012-11-29
  FDA Approved: COMETRIQ — Original Application (Exelixis, Inc.)

  The FDA approved Cometriq (cabozantinib) from Exelixis as the original application for the treatment of metastatic medullary thyroid carcino…

• FDA approval · 2012-10-09
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approves a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.

• FDA approval · 2011-04-06
  FDA Approved: CAPRELSA — Original Application (Genzyme Corporation)

  FDA approved Caprelsa (vandetanib) from Genzyme for the treatment of unresectable, metastatic medullary thyroid carcinoma.